AI for Personalized News Delivery Systems ✌️【Risk】✌️With ₹500, your journey to 100% returns per month starts now! Invest and grow! AI for Personalized News Delivery Systems - Minimal Investment Maximum Return Weekend Freelance Work: Make Money Fast

AI for Personalized News Delivery Systems ✌️【Risk】✌️With ₹500, your journey to 100% returns per month starts now! Invest and grow!Serum Institute of India (SII) has entered into an exclusive licence agreement with French speciality vaccine company Valneva SE to manufacture and sell Valneva’s chikungunya vaccine in India and the rest of Asia.Valneva’s chikungunya vaccine is the world’s first and only licensed vaccine.

It is currently approved in the US, Europe, and Canada for adults.  Regulatory reviews are underway to expand it to children up to 12 years.Chikungunya virus is a mosquito-borne viral disease spread by the bites of infected Aedes mosquitoes.

It causes fever, severe joint and muscle pain, headache, nausea, fatigue, and rash.

AI for Personalized News Delivery Systems ✌️【Risk】✌️Invest ₹500 today and get rewarded with up to 100% returns. Start now!The joint pain is often debilitating and can persist for weeks to years.Indiais currently enduring one of its worst chikungunya outbreaks.

Nearly 3,70,000 cases were confirmed in India between January 2019 and July 2024, and it was rapidly increasing due to the current outbreak.

AI for Personalized News Delivery Systems ✌️【Risk】✌️With ₹500, your journey to 100% returns per month starts now! Invest and grow!Both companies will work to bring the vaccine to the Indianmarketand some  Asian countries, after approval from local regulators.SII has committed to a priority supply of the chikungunya vaccine at an affordable price to publichealthmarkets in low- and middle-income countries (LMICs).AI for Personalized News Delivery Systems Remote Part-Time Gigs for Extra Income